CD38 and histiocytic sarcoma: Most recently, Zhang et al. described a 58-year-old woman with HS concurrent with FL who archived long-term remission after a combination of Tislelizumab (PD-1 inhibitor) with Daratumumab (anti-CD38 monoclonal antibody), Pazopanib (TKI), and GDP chemotherapy [106].